NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TCRX

Tscan Therapeutics Inc

Jun 20 • 04:00PM ET

1.44

Dollar change -0.02
Percentage change -1.37	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP ALLO NTLA FATE BLUE EDIT CLLS PGEN ADAP

| Held by: VTI SURI IWM VXF IBB IWO VTWO IWN IWC VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.09	Insider Own	22.56%	Shs Outstand	52.31M	Perf Week	-10.56%
Market Cap	81.49M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	25.44%	Shs Float	43.83M	Perf Month	19.01%
Enterprise Value	-73.16M	PEG	-	EPS next Q	-0.33	Inst Own	71.46%	Short Float	4.60%	Perf Quarter	-10.56%
Income	-131.48M	P/S	18.44	EPS this Y	-10.90%	Inst Trans	6.88%	Short Ratio	3.52	Perf Half Y	-52.16%
Sales	4.42M	P/B	0.39	EPS next Y	6.55%	ROA	-45.85%	Short Interest	2.01M	Perf YTD	-52.63%
Book/sh	3.71	P/C	0.32	EPS next 5Y	9.18%	ROE	-78.93%	52W Range	1.02 - 7.89	Perf Year	-80.65%
Cash/sh	4.45	P/FCF	-	EPS past 3/5Y	35.12% -14.41%	ROIC	-43.50%	52W High	-81.75%	Perf 3Y	-51.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.76% -	Gross Margin	20.11%	52W Low	41.18%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-16.55	EPS Y/Y TTM	47.90%	Oper. Margin	-3159.87%	Volatility	2.51% 5.77%	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.55	Sales Y/Y TTM	-70.15%	Profit Margin	-2974.08%	RSI (14)	44.26	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	8.55	EPS Q/Q	17.15%	SMA20	-7.87%	Beta	0.98	Target Price	8.50
Payout	-	Debt/Eq	0.46	Sales Q/Q	283.57%	SMA50	-1.74%	Rel Volume	0.78	Prev Close	1.46
Employees	194	LT Debt/Eq	0.44	Earnings	May 06 BMO	SMA200	-52.75%	Avg Volume	572.72K	Price	1.44
IPO	Jul 16, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	10.87% 100.09%	Trades		Volume	449,515	Change	-1.37%

Date	Action	Analyst	Rating Change	Price Target Change
May-16-24	Initiated	BTIG Research	Buy	$12
May-13-24	Initiated	Needham	Buy	$11
Jun-22-23	Initiated	Wedbush	Outperform	$8

May-28-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-06-25 08:20AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-25 04:53PM	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Mar-31-25 07:00AM	TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 07:00AM	TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access (GlobeNewswire)
Mar-05-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.76%
Feb-18-25 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Jan-10-25 09:35AM	Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks (Zacks)
Dec-26-24 07:00AM	TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium (GlobeNewswire) +6.87%
Dec-23-24 07:00AM	TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank (GlobeNewswire)
Dec-09-24 05:45PM	TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -28.23%
08:00AM	Loading…
Dec-05-24 08:00AM	TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years (GlobeNewswire) -5.39%
Dec-02-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Heme Development Strategy (GlobeNewswire)
Nov-12-24 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:43AM	TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks)
Nov-05-24 09:15AM	TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-04-24 09:05AM	TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting (GlobeNewswire)
Aug-29-24 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-14-24 07:00AM	TScan Therapeutics Announces Updates to its Board of Directors (GlobeNewswire) -6.67%
May-30-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies (GlobeNewswire) -6.41%
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-13-24 01:53PM	TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:15AM	Loading…
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:09AM	Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target (MT Newswires)
07:00AM	TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors (GlobeNewswire)
May-01-24 10:01AM	TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +11.66%
Apr-24-24 04:05PM	TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
11:03AM	TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-22-24 05:01PM	TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Apr-19-24 10:05AM	TScan Therapeutics Announces Closing of Upsized Public Offering (GlobeNewswire)
Apr-17-24 12:30AM	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering (GlobeNewswire) -5.33%
Apr-16-24 04:25PM	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering (GlobeNewswire) -7.28%
04:01PM	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities (GlobeNewswire)
Apr-08-24 08:00AM	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer (GlobeNewswire)
Apr-02-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.11%
Mar-17-24 02:58PM	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With (InvestorPlace)
Mar-07-24 01:44PM	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline (GuruFocus.com)
Mar-06-24 01:51PM	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-26-24 07:00AM	TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-19-24 05:49AM	TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? (Zacks)
Feb-14-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-06-24 07:00AM	TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development (GlobeNewswire) +6.67%
Jan-29-24 07:00AM	TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (GlobeNewswire)
Jan-18-24 07:00AM	TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire) -9.62%
Jan-04-24 07:00AM	TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-09-23 12:00PM	TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-07-23 07:00AM	TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations (GlobeNewswire)
Dec-06-23 08:50AM	Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why (Zacks)
Dec-04-23 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.56% +10.46%
07:00AM	TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer (GlobeNewswire)
Dec-01-23 09:55AM	Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect? (Zacks)
Nov-30-23 07:00AM	TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years (GlobeNewswire) +12.98%
Nov-27-23 12:00PM	TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
Nov-20-23 08:50AM	TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -13.83%
Nov-15-23 12:00PM	What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know (Zacks)
Nov-09-23 08:25AM	TScan Therapeutics Inc (TCRX) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
07:00AM	TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-23 07:00AM	TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting (GlobeNewswire) +11.03%
Nov-02-23 09:05AM	TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +7.73%
Oct-12-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why (Zacks)
Sep-27-23 09:06AM	TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-05-23 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME (GlobeNewswire) +10.96%
Aug-16-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-10-23 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:25AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jun-29-23 07:00AM	TScan Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
Jun-15-23 07:42AM	Favourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock \ (Simply Wall St.)
Jun-06-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors (GlobeNewswire)
Jun-01-23 04:10PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +21.65%
04:05PM	TScan Therapeutics Announces Closing of Public Offering (GlobeNewswire)
07:00AM	TScan Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-26-23 12:37AM	TScan Therapeutics Announces Pricing of $140 Million Public Offering (GlobeNewswire) +31.28%
May-25-23 04:06PM	TScan Therapeutics Announces Launch of Proposed Public Offering (GlobeNewswire)
May-24-23 04:13PM	TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors (GlobeNewswire)
May-17-23 04:35PM	TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients (Benzinga) -10.53% -8.12%
07:00AM	TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting (GlobeNewswire)
May-11-23 07:33AM	Institutional investors control 30% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 112% (Simply Wall St.) -7.22%
May-10-23 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +42.65%
07:00AM	TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 01:29PM	Why Are TScan Therapeutics Shares Are Shooting Higher Today (Benzinga) +51.14%
09:00AM	Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease (GlobeNewswire)
May-02-23 04:42PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +26.22% +10.63%
Apr-10-23 07:00AM	TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors (GlobeNewswire)
Mar-31-23 08:00AM	TScan Therapeutics Announces CEO Transition (GlobeNewswire) -18.29%

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	May 19 '25	Buy	1.20	1,388,794	1,666,553	6,746,141	May 21 04:49 PM
Lynx1 Capital Management LP	10% Owner	May 20 '25	Buy	1.20	1,200,000	1,440,000	7,946,141	May 21 04:49 PM
Lynx1 Capital Management LP	10% Owner	Dec 13 '24	Buy	2.90	100,000	290,140	5,357,347	Dec 16 04:26 PM
Lynx1 Capital Management LP	10% Owner	Dec 12 '24	Buy	3.01	31,800	95,629	5,257,347	Dec 16 04:26 PM
Lynx1 Capital Management LP	10% Owner	Nov 15 '24	Buy	4.34	947	4,114	5,225,547	Nov 19 04:26 PM
Klencke Barbara	Director	Sep 23 '24	Buy	5.29	5,000	26,450	45,000	Sep 24 05:26 PM
Klencke Barbara	Director	Aug 23 '24	Buy	5.69	5,000	28,450	35,000	Aug 27 06:57 PM
Klencke Barbara	Director	Aug 26 '24	Buy	5.53	5,000	27,650	40,000	Aug 27 06:57 PM
ZDRAVESKI ZORAN	See Remarks	Aug 23 '24	Option Exercise	3.38	157,186	531,520	169,402	Aug 27 06:46 PM
ZDRAVESKI ZORAN	See Remarks	Aug 23 '24	Sale	5.78	164,686	952,116	4,716	Aug 27 06:46 PM
ZDRAVESKI ZORAN	Officer	Aug 23 '24	Proposed Sale	5.50	164,686	905,773		Aug 23 05:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRX

Tscan Therapeutics Inc

Upgrade your FINVIZ experience